Loading…
Loading…
CRL · NYSE · Healthcare
“A company trading at negative earnings with a $7.7B valuation demands extraordinary scrutiny of underlying business fundamentals before any reasonable intrinsic value assessment.”
— In the voice of Graham
Estimate fair value using the Graham Number, earnings-based model, and PEG-adjusted valuation. Three independent methods averaged together.
Market Cap
$7.73B
P/E Ratio
-53.57
Forward P/E
—
EPS
$-2.91
PEG Ratio
-1.63
Book Value
$63.85
Dividend Yield
—
Profit Margin
-3.59%
ROE
-4.56%
Use the interactive fair value with pre-loaded data for Charles River Laboratories International Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for CRL: